KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EBT (2016 - 2025)

Historic EBT for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $3.1 billion.

  • Bristol Myers Squibb's EBT rose 8579.95% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 billion, marking a year-over-year increase of 21675.87%. This contributed to the annual value of -$8.4 billion for FY2024, which is 19927.73% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported EBT of $3.1 billion as of Q3 2025, which was up 8579.95% from $1.8 billion recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year EBT high stood at $3.1 billion for Q3 2025, and its period low was -$11.5 billion during Q1 2024.
  • Its 5-year average for EBT is $1.2 billion, with a median of $1.9 billion in 2022.
  • Its EBT has fluctuated over the past 5 years, first soared by 93223.68% in 2021, then plummeted by 51574.01% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's EBT stood at $1.9 billion in 2021, then rose by 0.05% to $1.9 billion in 2022, then dropped by 9.95% to $1.7 billion in 2023, then tumbled by 89.55% to $175.0 million in 2024, then soared by 1679.43% to $3.1 billion in 2025.
  • Its last three reported values are $3.1 billion in Q3 2025, $1.8 billion for Q2 2025, and $3.0 billion during Q1 2025.